BioCryst CFO Anthony Doyle to resign effective April 9, 2025; search underway

BIOCRYST PHARMACEUTICALS INC

Anthony Doyle notified resignation as CFO effective April 9, 2025.
Resignation is not due to any disagreement with the company.
Company has initiated a search for a new CFO; Doyle will remain to assist transition.
Doyle joined in April 2020, helped launch ORLADEYO and strengthen financial position.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anthony Doyle

Chief Financial Officer

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2025-04-09
Filed: March 4, 2025, 6:59 PM ET

On February 28, 2025, Anthony Doyle, the Chief Financial Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Anthony Doyle resigned as Chief Financial Officer at BIOCRYST PHARMACEUTICALS INC.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On February 28, 2025, Anthony Doyle, the Chief Financial Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025.

View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-25-001231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.